This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): clostridium difficile toxoid vaccine
Description: ACAM-CDIFF is a vaccine consisting of inactivated Clostridium difficile toxins A and B designed to provide protection against CDAD/CDI in the prophylactic and therapeutic settings.
Deal Structure: In July 2008, Sanofi-aventis announced it reached an agreement with Acambis on the terms of a unanimously recommended cash offer for the entire issued and to be issued share capital of Acambis. The acquisition was completed in September 2008.
Additional information available to subscribers only: